Posted by Michael Wonder on 26 Nov 2025
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
25 November 2025 - People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
NICE has recommended obecabtagene autoleucel (Aucatzyl) for routine NHS use in England, offering new hope to over 150 people over the next the three years with relapsed or refractory B-cell acute lymphoblastic leukaemia, who have limited treatment options.
